All AbMole products are for research use only, cannot be used for human consumption.
GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes. In the intravenous glucose tolerance test, significant increases in the peak insulin response and insulin AUC (0-15 min) of 30-60% were reported in the GSK1292263 treatment group, compared with values in the vehicle control cohort. This insulin upregulation correlated with a significant increase in the glucose disposal rate.
Cell Experiment | |
---|---|
Cell lines | |
Preparation method | |
Concentrations | |
Incubation time |
Animal Experiment | |
---|---|
Animal models | male Sprague-Dawley rats |
Formulation | 0.9% sodium chloride solution |
Dosages | 3-30 mg/kg |
Administration |
Molecular Weight | 456.56 |
Formula | C23H28N4O4S |
CAS Number | 1032823-75-8 |
Solubility (25°C) | DMSO 22 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Jin Won Yang, et al. GPR119: a promising target for nonalcoholic fatty liver disease
Related GPR/FFAR Products |
---|
GPR84 antagonist 8
GPR84 antagonist 8 is a selective GPR84 antagonist. |
ML191
ML-191 is an antagonist of GPR55. |
CID1172084
CID1172084 is a selective GPR55 agonist (EC50=0.16 μM). |
ML 145
ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. |
PSN 375963 hydrochloride
PSN 375963 hydrochloride is a potent GPR119 agonist, with EC50s of 8.4 and 7.9 μM for human and mouse GPR119, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.